Tissue | Expression Dynamics | Abbreviation |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/CAMK2G_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/CAMK2G_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/CAMK2G_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/CAMK2G_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/CAMK2G_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:003559217 | Esophagus | ESCC | establishment of protein localization to extracellular region | 190/8552 | 360/18723 | 3.77e-03 | 1.53e-02 | 190 |
GO:007169210 | Esophagus | ESCC | protein localization to extracellular region | 193/8552 | 368/18723 | 5.01e-03 | 1.92e-02 | 193 |
GO:001631121 | Liver | HCC | dephosphorylation | 230/7958 | 417/18723 | 1.00e-07 | 1.96e-06 | 230 |
GO:000647021 | Liver | HCC | protein dephosphorylation | 162/7958 | 281/18723 | 1.91e-07 | 3.46e-06 | 162 |
GO:001097511 | Liver | HCC | regulation of neuron projection development | 220/7958 | 445/18723 | 1.68e-03 | 8.78e-03 | 220 |
GO:003559212 | Liver | HCC | establishment of protein localization to extracellular region | 176/7958 | 360/18723 | 7.96e-03 | 3.15e-02 | 176 |
GO:000930612 | Liver | HCC | protein secretion | 175/7958 | 359/18723 | 9.32e-03 | 3.57e-02 | 175 |
GO:000647015 | Oral cavity | OSCC | protein dephosphorylation | 162/7305 | 281/18723 | 1.56e-10 | 4.56e-09 | 162 |
GO:00163119 | Oral cavity | OSCC | dephosphorylation | 220/7305 | 417/18723 | 6.33e-09 | 1.34e-07 | 220 |
GO:001097510 | Oral cavity | OSCC | regulation of neuron projection development | 210/7305 | 445/18723 | 2.35e-04 | 1.52e-03 | 210 |
GO:000930610 | Oral cavity | OSCC | protein secretion | 169/7305 | 359/18723 | 1.04e-03 | 5.34e-03 | 169 |
GO:003559210 | Oral cavity | OSCC | establishment of protein localization to extracellular region | 169/7305 | 360/18723 | 1.21e-03 | 6.08e-03 | 169 |
GO:00716929 | Oral cavity | OSCC | protein localization to extracellular region | 172/7305 | 368/18723 | 1.40e-03 | 6.79e-03 | 172 |
GO:000647023 | Oral cavity | EOLP | protein dephosphorylation | 72/2218 | 281/18723 | 1.19e-10 | 1.35e-08 | 72 |
GO:001631114 | Oral cavity | EOLP | dephosphorylation | 85/2218 | 417/18723 | 3.19e-07 | 9.47e-06 | 85 |
GO:001097515 | Oral cavity | EOLP | regulation of neuron projection development | 86/2218 | 445/18723 | 2.75e-06 | 6.05e-05 | 86 |
GO:0014733 | Oral cavity | EOLP | regulation of skeletal muscle adaptation | 6/2218 | 15/18723 | 5.31e-03 | 2.76e-02 | 6 |
GO:000930616 | Oral cavity | EOLP | protein secretion | 59/2218 | 359/18723 | 5.67e-03 | 2.92e-02 | 59 |
GO:003559216 | Oral cavity | EOLP | establishment of protein localization to extracellular region | 59/2218 | 360/18723 | 6.02e-03 | 3.01e-02 | 59 |
GO:007169215 | Oral cavity | EOLP | protein localization to extracellular region | 60/2218 | 368/18723 | 6.31e-03 | 3.13e-02 | 60 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CAMK2G | SNV | Missense_Mutation | | c.191T>C | p.Ile64Thr | p.I64T | Q13555 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.998) | TCGA-A8-A07R-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Ancillary | zoledronic | SD |
CAMK2G | SNV | Missense_Mutation | novel | c.319N>G | p.Tyr107Asp | p.Y107D | Q13555 | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.637) | TCGA-A8-A08B-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR |
CAMK2G | SNV | Missense_Mutation | novel | c.532C>A | p.Pro178Thr | p.P178T | Q13555 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.998) | TCGA-E2-A56Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
CAMK2G | insertion | Frame_Shift_Ins | novel | c.316_317insGTGCAGAAGACATGGTTTCTGTCCTG | p.Glu106GlyfsTer41 | p.E106Gfs*41 | Q13555 | protein_coding | | | TCGA-A8-A08B-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR |
CAMK2G | insertion | Nonsense_Mutation | novel | c.520_521insGACATACAA | p.Phe174delinsTer | p.F174delins* | Q13555 | protein_coding | | | TCGA-AN-A03X-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
CAMK2G | SNV | Missense_Mutation | | c.1033G>C | p.Glu345Gln | p.E345Q | Q13555 | protein_coding | tolerated_low_confidence(0.31) | benign(0.062) | TCGA-DS-A1OC-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | gemcitabine | SD |
CAMK2G | SNV | Missense_Mutation | novel | c.709G>A | p.Glu237Lys | p.E237K | Q13555 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.986) | TCGA-VS-A953-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD |
CAMK2G | SNV | Missense_Mutation | novel | c.168G>T | p.Gln56His | p.Q56H | Q13555 | protein_coding | deleterious_low_confidence(0) | benign(0.182) | TCGA-VS-A9U7-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
CAMK2G | SNV | Missense_Mutation | | c.787N>A | p.Ala263Thr | p.A263T | Q13555 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.991) | TCGA-A6-5665-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
CAMK2G | SNV | Missense_Mutation | | c.712N>C | p.Trp238Arg | p.W238R | Q13555 | protein_coding | deleterious_low_confidence(0) | probably_damaging(1) | TCGA-AA-3663-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
818 | CAMK2G | KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, ENZYME | | LINIFANIB | LINIFANIB | |
818 | CAMK2G | KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, ENZYME | | LITHIUM | LITHIUM | 12614997 |
818 | CAMK2G | KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, ENZYME | inhibitor | 178102336 | BOSUTINIB | |
818 | CAMK2G | KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, ENZYME | | CYC-116 | CYC-116 | |
818 | CAMK2G | KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, ENZYME | | ANTIDEPRESSANTS | | 12614997 |
818 | CAMK2G | KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, ENZYME | | GEFITINIB | GEFITINIB | |
818 | CAMK2G | KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, ENZYME | | SP-600125 | SP-600125 | |
818 | CAMK2G | KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, ENZYME | | TAE-684 | TAE-684 | |
818 | CAMK2G | KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, ENZYME | | LY-2090314 | LY-2090314 | |
818 | CAMK2G | KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, ENZYME | | DOVITINIB | DOVITINIB | |